查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179528

左心房附件(LAA)閉合裝置市場：副產品（心內膜/心外膜LAA裝置）、最終用途（醫院、門診手術中心等）：全球機會分析和行業預測2021-2031

Left Atrial Appendage (LAA) Closure Device Market By Product (Endocardial LAA Devices, Epicardial LAA Devices), By End Use (Hospitals, Ambulatory Surgery Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 318 Pages | 商品交期: 2-3個工作天內

價格

從 2022 年到 2031 年，全球左心耳 (LAA) 閉合裝置市場將以 20.97% 的複合年增長率增長，從 2021 年的 12.769 億美元，預計到 2031 年達到 82.181 億美元。

世界上左心耳（LAA）封堵器植入心臟，旨在降低非瓣膜性心房顫動患者因左心耳（LAA）血栓栓塞的風險增加。 該裝置以機械方式封閉左心耳，防止左心耳凝塊進入人體循環。 LAA 封堵可降低與心房顫動相關的中風風險。 但是，它本身並不治療心房顫動。 左心耳封堵術對需要心臟手術和心房顫動的人很有用。 該程序對心房顫動患者也有效。

預計心房顫動患病率的上升將增加對左心耳封堵器的需求。 房顫是先天性心髒病患者最常見的房性心律失常之一。 此外，房顫的發病率被認為隨著年齡的增長而增加，因為老年人更容易患心律失常、缺血性中風和房顫。 這些因素有望提高左心耳 (LAA) 封堵器的市場價值。

但是，替代品的可用性和左心耳閉合裝置的高成本可能會對市場擴張產生負面影響。 口服抗凝劑是左心耳封堵器的傳統替代品，是非瓣膜性心房顫動醫生的廣泛首選。 利伐沙班、達比加群、阿□沙班和依度沙班等非維生素口服抗凝劑 (NOAC) 的開發促進了在卒中治療中易發生血栓栓塞事件的患者中使用口服抗凝劑。 這些因素預計將限制左心耳 (LAA) 封堵器市場的增長。

隨著世界各地的各種企業陷入停頓，COVID-19 大流行帶來了一些不確定性，導致嚴重的經濟損失。 美國、中國等左心耳封堵器主要生產國實施進出口限制，市場受到重創。 COVID-19可能促進血栓炎症級聯反應，強化凝血，增加心房顫動患者發生心肌梗死的風險。 大流行期間對 ICU 病床的限制將顯著限制心臟手術的實施，包括左心房關閉，並減少左心房關閉裝置的使用。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析
  • 監管準則
  • 價值鏈分析
  • 市場份額分析
  • 關鍵法規分析
  • 專利情況

第 4 章。左心耳 (LAA) 閉合裝置市場：按產品分類

  • 概覽
    • 市場規模和預測
  • 心內膜 LAA 裝置
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 心外膜 LAA 裝置
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章左心耳 (LAA) 閉合裝置市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 門診手術中心
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章。左心房附件 (LAA) 閉合裝置 (LAA) 市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按產品
    • 北美市場規模和預測：按最終用戶分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按產品
    • 歐洲市場規模和預測：按最終用戶分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 英國
      • 法國
      • 西班牙
      • 意大利
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按產品
    • 亞太市場規模和預測：按最終用戶分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 中國
      • 日本
      • 印度
      • 韓國
      • 澳大利亞
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按產品
    • LAMEA 市場規模和預測：按最終用戶分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 阿聯酋
      • 南非
      • LAMEA 的其餘部分

第七章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第八章公司簡介

  • sentreheart, inc.
  • Boston Scientific Corporation
  • AtriCure, Inc.
  • Abbott Laboratories
  • Occlutech
  • lifetech scientific corporation
  • Cardia, Inc.
  • Aegis Medical Group.
  • Biosense Webster, Inc.
  • Johnson & Johnson Services, Inc.
Product Code: A03358

The global left atrial appendage (LAA) closure device market is envisioned to garner $8,218.10 million by 2031, growing from $1,276.90 million in 2021 at a CAGR of 20.97% from 2022 to 2031.

The global Left Atrial Appendage (LAA) Closure device is implanted in the heart and is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the circulation of the blood in the body. LAA closure reduces the stroke risk associated with atrial fibrillation. But, it doesn't treat the AFib itself. Left atrial appendage closure can benefit people who need heart surgery and also have atrial fibrillation. The procedure is also helpful for those who have atrial fibrillation.

The rising prevalence of atrial fibrillation is anticipated to augment the need for left atrial appendage closure devices. Atrial fibrillation was one the most prevalent atrial arrhythmia in patients suffering from congenital heart disease. Additionally, the aging population will increase atrial fibrillation disease incidences, as elderly adults are more susceptible to arrhythmia, ischemic stroke disease, and atrial fibrillation. Such factors are anticipated to drive the Left Atrial Appendage (LAA) Closure device market value.

However, the availability of alternatives and the high cost of left atrial appendage atrial closure devices may negatively impact the market expansion. Oral anticoagulation is the conventional alternative to left atrial appendage closure devices and is extensively preferred by doctors with non-valvular atrial fibrillation. The development of non-vitamin oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban have facilitated the use of oral anti-coagulants among patients that are susceptible to thromboembolic events in stroke management. Such factors are anticipated to restrict the Left Atrial Appendage (LAA) Closure device market growth.

The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. There were import-export restrictions laid down on major Left Atrial Appendage (LAA) Closure device-producing countries such as the United States and China, which imposed significant challenges on the market. COVID-19 virus enhances the thrombo-inflammatory cascade, which intensifies coagulation and may increase the risk of cardiac embolism in patients with AF. The limitations regarding the ICU beds during the pandemic represent a major restriction in performing heart surgeries including left atrial appendage closure procedures, thereby reducing the usage of left atrial appendage closure devices.

The key players profiled in the Left Atrial Appendage (LAA) Closure Device market report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the left atrial appendage (LAA) closure device market analysis from 2021 to 2031 to identify the prevailing left atrial appendage (LAA) closure device market opportunities.
  • Market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
  • An in-depth analysis of the left atrial appendage (LAA) closure device market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global left atrial appendage (LAA) closure device market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Endocardial LAA Devices
  • Epicardial LAA Devices

By End Use

  • Hospitals
  • Ambulatory Surgery Centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • sentreheart, inc.
    • Boston Scientific Corporation
    • AtriCure, Inc.
    • Abbott Laboratories
    • Occlutech
    • lifetech scientific corporation
    • Cardia, Inc.
    • Aegis Medical Group.
    • Biosense Webster, Inc.
    • Johnson & Johnson Services, Inc.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market
  • 3.7.Regulatory Guidelines
  • 3.8.Value Chain Analysis
  • 3.9.Market Share Analysis
  • 3.10.Key Regulation Analysis
  • 3.11.Patent Landscape

CHAPTER 4: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Endocardial LAA Devices
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Epicardial LAA Devices
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Ambulatory Surgery Centers
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Product
    • 6.2.3 North America Market size and forecast, by End Use
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Product
      • 6.2.4.1.2 Market size and forecast, by End Use
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Product
      • 6.2.4.2.2 Market size and forecast, by End Use
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Product
      • 6.2.4.3.2 Market size and forecast, by End Use
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Product
    • 6.3.3 Europe Market size and forecast, by End Use
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Product
      • 6.3.4.1.2 Market size and forecast, by End Use
      • 6.3.4.2 United Kingdom
      • 6.3.4.2.1 Market size and forecast, by Product
      • 6.3.4.2.2 Market size and forecast, by End Use
      • 6.3.4.3 France
      • 6.3.4.3.1 Market size and forecast, by Product
      • 6.3.4.3.2 Market size and forecast, by End Use
      • 6.3.4.4 Spain
      • 6.3.4.4.1 Market size and forecast, by Product
      • 6.3.4.4.2 Market size and forecast, by End Use
      • 6.3.4.5 Italy
      • 6.3.4.5.1 Market size and forecast, by Product
      • 6.3.4.5.2 Market size and forecast, by End Use
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Product
      • 6.3.4.6.2 Market size and forecast, by End Use
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Product
    • 6.4.3 Asia-Pacific Market size and forecast, by End Use
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Product
      • 6.4.4.1.2 Market size and forecast, by End Use
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Product
      • 6.4.4.2.2 Market size and forecast, by End Use
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Product
      • 6.4.4.3.2 Market size and forecast, by End Use
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Product
      • 6.4.4.4.2 Market size and forecast, by End Use
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Product
      • 6.4.4.5.2 Market size and forecast, by End Use
      • 6.4.4.6 Rest Of Asia Pacific
      • 6.4.4.6.1 Market size and forecast, by Product
      • 6.4.4.6.2 Market size and forecast, by End Use
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Product
    • 6.5.3 LAMEA Market size and forecast, by End Use
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Product
      • 6.5.4.1.2 Market size and forecast, by End Use
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Product
      • 6.5.4.2.2 Market size and forecast, by End Use
      • 6.5.4.3 UAE
      • 6.5.4.3.1 Market size and forecast, by Product
      • 6.5.4.3.2 Market size and forecast, by End Use
      • 6.5.4.4 South Africa
      • 6.5.4.4.1 Market size and forecast, by Product
      • 6.5.4.4.2 Market size and forecast, by End Use
      • 6.5.4.5 Rest of LAMEA
      • 6.5.4.5.1 Market size and forecast, by Product
      • 6.5.4.5.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 sentreheart, inc.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Boston Scientific Corporation
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 AtriCure, Inc.
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Abbott Laboratories
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Occlutech
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 lifetech scientific corporation
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Cardia, Inc.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Aegis Medical Group.
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Biosense Webster, Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Johnson & Johnson Services, Inc.
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 2. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR ENDOCARDIAL LAA DEVICES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR ENDOCARDIAL LAA DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR EPICARDIAL LAA DEVICES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR EPICARDIAL LAA DEVICES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. GLOBAL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 7. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 18. U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 19. CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 20. CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 21. MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 22. MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 23. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 24. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 25. EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 26. GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 27. GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 28. UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 29. UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 30. FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 31. FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 32. SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 33. SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 34. ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 35. ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 36. REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 37. REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 38. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 39. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 40. ASIA-PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 41. CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 42. CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 43. JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 44. JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 45. INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 46. INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 47. SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 48. SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 49. AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 50. AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 51. REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 52. REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 53. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 54. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 55. LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 56. BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 57. BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 58. SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 59. SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 60. UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 61. UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 62. SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 63. SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 64. REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT, 2021-2031 ($MILLION)
  • TABLE 65. REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE, 2021-2031 ($MILLION)
  • TABLE 66.SENTREHEART, INC.: COMPANY SNAPSHOT
  • TABLE 67.SENTREHEART, INC.: OPERATING SEGMENTS
  • TABLE 68.SENTREHEART, INC.: PRODUCT PORTFOLIO
  • TABLE 69.SENTREHEART, INC.: NET SALES,
  • TABLE 70.SENTREHEART, INC.: KEY STRATERGIES
  • TABLE 71.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 72.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 73.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 74.BOSTON SCIENTIFIC CORPORATION: NET SALES,
  • TABLE 75.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 76.ATRICURE, INC.: COMPANY SNAPSHOT
  • TABLE 77.ATRICURE, INC.: OPERATING SEGMENTS
  • TABLE 78.ATRICURE, INC.: PRODUCT PORTFOLIO
  • TABLE 79.ATRICURE, INC.: NET SALES,
  • TABLE 80.ATRICURE, INC.: KEY STRATERGIES
  • TABLE 81.ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 82.ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 83.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 84.ABBOTT LABORATORIES: NET SALES,
  • TABLE 85.ABBOTT LABORATORIES: KEY STRATERGIES
  • TABLE 86.OCCLUTECH: COMPANY SNAPSHOT
  • TABLE 87.OCCLUTECH: OPERATING SEGMENTS
  • TABLE 88.OCCLUTECH: PRODUCT PORTFOLIO
  • TABLE 89.OCCLUTECH: NET SALES,
  • TABLE 90.OCCLUTECH: KEY STRATERGIES
  • TABLE 91.LIFETECH SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
  • TABLE 92.LIFETECH SCIENTIFIC CORPORATION: OPERATING SEGMENTS
  • TABLE 93.LIFETECH SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
  • TABLE 94.LIFETECH SCIENTIFIC CORPORATION: NET SALES,
  • TABLE 95.LIFETECH SCIENTIFIC CORPORATION: KEY STRATERGIES
  • TABLE 96.CARDIA, INC.: COMPANY SNAPSHOT
  • TABLE 97.CARDIA, INC.: OPERATING SEGMENTS
  • TABLE 98.CARDIA, INC.: PRODUCT PORTFOLIO
  • TABLE 99.CARDIA, INC.: NET SALES,
  • TABLE 100.CARDIA, INC.: KEY STRATERGIES
  • TABLE 101.AEGIS MEDICAL GROUP.: COMPANY SNAPSHOT
  • TABLE 102.AEGIS MEDICAL GROUP.: OPERATING SEGMENTS
  • TABLE 103.AEGIS MEDICAL GROUP.: PRODUCT PORTFOLIO
  • TABLE 104.AEGIS MEDICAL GROUP.: NET SALES,
  • TABLE 105.AEGIS MEDICAL GROUP.: KEY STRATERGIES
  • TABLE 106.BIOSENSE WEBSTER, INC.: COMPANY SNAPSHOT
  • TABLE 107.BIOSENSE WEBSTER, INC.: OPERATING SEGMENTS
  • TABLE 108.BIOSENSE WEBSTER, INC.: PRODUCT PORTFOLIO
  • TABLE 109.BIOSENSE WEBSTER, INC.: NET SALES,
  • TABLE 110.BIOSENSE WEBSTER, INC.: KEY STRATERGIES
  • TABLE 111.JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
  • TABLE 112.JOHNSON & JOHNSON SERVICES, INC.: OPERATING SEGMENTS
  • TABLE 113.JOHNSON & JOHNSON SERVICES, INC.: PRODUCT PORTFOLIO
  • TABLE 114.JOHNSON & JOHNSON SERVICES, INC.: NET SALES,
  • TABLE 115.JOHNSON & JOHNSON SERVICES, INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET SEGMENTATION
  • FIGURE 2.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031
  • FIGURE 3.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.REGULATORY GUIDELINES
  • FIGURE 13.VALUE CHAIN ANALYSIS
  • FIGURE 14.MARKET SHARE ANALYSIS
  • FIGURE 15.KEY REGULATION ANALYSIS
  • FIGURE 16.PATENT ANALYSIS BY COMPANY
  • FIGURE 17.PATENT ANALYSIS BY COUNTRY
  • FIGURE 18.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,BY PRODUCT,2021(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF ENDOCARDIAL LAA DEVICES LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF EPICARDIAL LAA DEVICES LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
  • FIGURE 21.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,BY END USE,2021(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF HOSPITALS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF AMBULATORY SURGERY CENTERS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF OTHERS LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031(%)
  • FIGURE 25.LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET BY REGION,2021
  • FIGURE 26.U.S. LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 27.CANADA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 28.MEXICO LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 29.GERMANY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 30.UNITED KINGDOM LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF EUROPE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 39.AUSTRALIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA PACIFIC LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 43.UAE LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 44.SOUTH AFRICA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 45.REST OF LAMEA LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET,2021-2031($MILLION)
  • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 50.COMPETITIVE DASHBOARD
  • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 52.SENTREHEART, INC..: NET SALES ,($MILLION)
  • FIGURE 53.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 54.ATRICURE, INC..: NET SALES ,($MILLION)
  • FIGURE 55.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
  • FIGURE 56.OCCLUTECH.: NET SALES ,($MILLION)
  • FIGURE 57.LIFETECH SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 58.CARDIA, INC..: NET SALES ,($MILLION)
  • FIGURE 59.AEGIS MEDICAL GROUP..: NET SALES ,($MILLION)
  • FIGURE 60.BIOSENSE WEBSTER, INC..: NET SALES ,($MILLION)
  • FIGURE 61.JOHNSON & JOHNSON SERVICES, INC..: NET SALES ,($MILLION)